Latest / This Week In Medicine
NEJM April 2026 First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
This clinical study explores the impact of zongertinib, an innovative oral medication designed to treat a specific subtype of advanced lung cancercharacterized by HER2 mutations. By selectively targeting these mutated proteins while avoiding healthy receptors, the drug aims to destroy tumors with minimal toxic side effects compared to traditional therapies. The trial demonstrated a high objective response rate of 76% in previously untreated patients, while also showing significant promise in shrinking active brain metastases. Ultimately, the research positions zongertinib as a highly…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.